The clinical problem
Cancer pain is frequently multi-mechanistic (nociceptive and neuropathic) and can remain troublesome despite guideline-based analgesia, including opioids. This drives interest in adjuncts that act through complementary pathways.
Rationale for cannabinoids
Cannabinoids modulate pain signalling through the endocannabinoid system and other targets, a mechanism distinct from opioids and NSAIDs. In practice they are considered as an adjunct within a multimodal plan — potentially helping pain, and sometimes sleep, appetite or nausea — rather than as first-line monotherapy.
What the evidence says
The evidence base is heterogeneous and evolving; benefits, where seen, are often modest and must be weighed against adverse effects. Review the source-linked studies in the clinical evidence library and the oncology research view, and appraise them for your patient rather than generalising.
Practical considerations
Consider cannabinoids where standard analgesia is inadequate or poorly tolerated, individualise the CBD:THC ratio, and titrate carefully (see the dosage guide). Screen for interactions — relevant in polypharmacy — and monitor for adverse effects. Decisions should align with oncology and palliative-care management.
Put this into practice
Move from reference to a compliant prescription and proforma invoice with the EndoCann clinic tools.